Impact of tacrolimus versus cyclosporin A on renal function during the first year after heart transplant
Open Access
- 23 May 2020
- journal article
- research article
- Published by Wiley in ESC Heart Failure
- Vol. 7 (4), 1842-1849
- https://doi.org/10.1002/ehf2.12749
Abstract
Aims Nephrotoxicity of calcineurin inhibitors (CNIs) is associated with adverse events in patients undergoing heart transplant (HTx), although studies directly comparing tacrolimus (TAC) versus cyclosporin A (CsA), especially in combination with everolimus and low‐dose CNIs approach, are limited. Thus, we sought to investigate the associations of TAC and CsA with clinical outcomes in HTx recipients, with specific focus on renal function. Methods and results From August 2007 to February 2017, 72 consecutive patients (39 treated with TAC vs. 33 with CsA) receiving de novo HTx in a single transplant centre were retrospectively evaluated. We used the instrumental variable method to account for unmeasured confounding. The study outcomes were percentage change in estimated glomerular filtration rates (eGFR) (safety endpoint) and biopsy‐proven acute rejection (efficacy endpoint) within the first year after HTx. The enrolled patients (median age 40 years) were predominantly men (68%). There were no significant differences in baseline characteristics, including eGFR (64.8 [45.7–96.4] mL/min/1.73 m2 in TAC vs. 65.6 [57.9–83.0] mL/min/1.73 m2 for CsA; P = 0.48), other than sex (male, 49% for TAC vs. 91% for CsA; P < 0.001) between the two groups. Within the first year after HTx, 23 (59%) in the TAC group switched mycophenolate mofetil to everolimus, whereas 16 (48%) in the CsA group (P = 0.52). At 12 months, the rates of mortality and end‐stage renal disease requiring renal replacement therapies were both 0%. In the instrumental variable analysis, no differences in renal function as well as graft rejection for 1 year after HTx existed between the TAC and CsA groups. These results were similar when taking into account of everolimus use. Conclusions Irrespective of everolimus use with low‐dose CNIs, our analysis using the instrumental variable method showed no differences in renal function as well as graft rejection during the first year after HTx between HTx recipients who received TAC or CsA.Keywords
This publication has 35 references indexed in Scilit:
- Everolimus With Reduced Cyclosporine Versus MMF With Standard Cyclosporine in De Novo Heart Transplant RecipientsTransplantation, 2009
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009
- Chronic Kidney Disease after Nonrenal Solid-Organ TransplantationJournal of the American Society of Nephrology, 2007
- Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1-Year ReportAmerican Journal of Transplantation, 2006
- Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart RejectionThe Journal of Heart and Lung Transplantation, 2005
- Chronic Renal Failure after Transplantation of a Nonrenal OrganThe New England Journal of Medicine, 2003
- Efficacy and safety of tacrolimus (TAC) vs. cyclosporine microemulsion (CME) in de novo cardiac transplant recipients: 6-month resultsThe Journal of Heart and Lung Transplantation, 2003
- A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimusThe Journal of Heart and Lung Transplantation, 1999
- Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusionKidney International, 1993
- Cyclosporine-Associated Chronic NephropathyThe New England Journal of Medicine, 1984